Načítá se...
Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
Median survival for patients with metastatic pancreatic cancer (MPC) treated with combination chemotherapeutic agents such as gemcitabine-based regimens and FOLFIRINOX is currently less than 12 months. This highlights the need for more efficacious first-line, as well as second-line therapies. Nanoli...
Uloženo v:
| Vydáno v: | Therap Adv Gastroenterol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5484436/ https://ncbi.nlm.nih.gov/pubmed/28804517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17705328 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|